13-Apr-2018 - sanofi-aventis Groupe

Sanofi to invest €350 million in Canadian vaccine facility

Toronto facility is one of the largest-ever investments by Sanofi in a single building

Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company’s Canadian operations and its commitment to advancing public health around the world.

The announcement will be made during an event today at Sanofi Pasteur’s Toronto facility. Attendees will include the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, Government of Canada, the Honourable Steven Del Duca, Minister of Economic Development and Growth, Government of Ontario, and members of Sanofi’s executive leadership.

“Canada has a strong legacy in the research and development of vaccines.  With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe,” said David Loew, Executive Vice President and Head of Sanofi Pasteur. “Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.”

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.

“This project is one of the most important investments for the Sanofi global industrial network,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi. “It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.”

Facts, background information, dossiers
  • Sanofi-aventis
  • Sanofi Pasteur
More about Sanofi-Aventis
  • News

    Evotec receives € 3 million payment from Sanofi

    Evotec SE announced successful achievement of a third milestone in their diabetes research alliance with Sanofi (“TargetBCD”), resulting in a payment of € 3 m to Evotec. This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy progr ... more

    Evotec expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse

    Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi. Evotec has had a successful track record of managing Sanofi’s powder compounds at its Toulouse site since 2015. Under the terms of the new agreement, Sanofi will t ... more

    Sanofi and Google to develop new healthcare Innovation Lab

    Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. “We stand on the forefront of a new age for biology and human health, with t ... more

  • Companies

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    sanofi-aventis Groupe

    One of the world's leading pharmaceutical companies and number 1 in Europe. Sanofi-aventis' pharmaceuticals business focuses on six therapeutic areas: diabetes, oncology, thrombosis, cardiovascular diseases, central nervous system (CNS) and internal medicine. About 100,000 employees worl ... more